Five years ago, pharmaceutical packaging and drug delivery were treated as downstream manufacturing functions. The packaging engineer’s job description had been stable for two decades: mechanical engineering depth, container-closure expertise, regulatory familiarity for primary packaging, supplier management, and operational excellence in fill-finish handoff.
That job description is now obsolete.
Drug delivery and packaging have transformed into a strategic differentiation category in pharmaceutical product development. Connected autoinjectors are commercial reality. Smart packaging with NFC and RFID is moving from pilot to mainstream. Large-volume subcutaneous delivery has emerged as a major biologics format. Sustainability requirements driven by EU regulation are reshaping material selection. Combination products require device-drug expertise that did not exist as a discrete capability in most pharma organizations.
The talent profile required to lead this work in 2026 looks fundamentally different than it did in 2020. Most pharma manufacturers have not adjusted their hiring profiles to match. The result is a structural skills gap that is now constraining product launches and delivery system competitive position.
Five forces converged to redefine packaging and delivery talent requirements between 2020 and 2026.
Connected devices became commercial. Smart drug delivery systems with adherence monitoring, dosing precision tracking, and real-world evidence generation moved from concept to mainstream commercial deployment. Per Alira Health’s 2026 global drug delivery system trends report, smart device technologies including connected autoinjectors are gaining traction for their ability to monitor treatment adherence, improve dosing precision, and enhance overall safety, particularly in diabetes, GLP-1 therapies, and rare chronic diseases.
The practical implication: roles that were historically mechanical engineering positions now require software engineering, IoT integration, data science, and connected health platform integration expertise. The packaging engineer of 2020 did not need these skills. The packaging engineer of 2026 cannot effectively run modern programs without them.
Large-volume subcutaneous delivery emerged as a major format. Per Alira Health, biologics market growth of 14% in 2024, reaching $474 billion, is driving large-volume subcutaneous delivery demand. Approximately 15% of clinical-stage biologics now fall into the large-volume subcutaneous category, with nearly half requiring 2 to 5 mL delivery volumes that essentially did not exist as a commercial category five years ago.
Developing and manufacturing these formats requires expertise in viscosity management, container compatibility, injection mechanics for high-volume delivery, and patient usability for self-administration of larger doses. The talent that holds this expertise developed it through on-the-job experience at the small number of companies pioneering the format.
Sustainability shifted from peripheral to mandatory. The European Union’s Packaging and Packaging Waste Regulation, which mandates pharmaceutical packaging recyclability by 2035, has driven sustainability requirements into the core of packaging engineering work. Per Drug Delivery Leader’s December 2025 industry analysis, sustainability is now becoming part of new business tenders, with pharma manufacturers integrating environmental stewardship into their procurement decisions.
This represents a fundamental change in the packaging engineer skill set. Material science expertise, lifecycle analysis, recyclability engineering, and ESG-aligned procurement decision-making were peripheral skills in 2020. They are now central. Most packaging engineers in the industry today did not build their careers around these competencies, and the talent pool with deep sustainability fluency is small.
Patient-centric design moved from afterthought to differentiator. Aging-in-place trends and the rise of self-administration have shifted drug delivery from professional clinical environments to home settings, where patients and non-professional caregivers handle administration. Per Drug Delivery Leader, this requires understanding the entire user interaction with the delivery method, including packaging, labeling, instructions for use, and the device itself.
Human factors engineering, usability research, and patient experience design are now core competencies in delivery system development. Most academic mechanical engineering and pharmaceutical sciences programs do not produce graduates with these competencies. The talent pool that has them was largely developed in medical device companies, not in pharma manufacturing.
Combination products restructured the regulatory and supply chain landscape. Pre-validated, off-the-shelf autoinjector platforms from companies like Ypsomed, SHL Medical, and Owen Mumford have become the industry standard for many biologics, replacing custom device development. Per Alira Health, pharmaceutical companies increasingly favor these platforms to reduce costs, accelerate time to market, and lower regulatory risk.
Managing combination product programs requires regulatory expertise spanning FDA Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) frameworks, supplier relationship management for global device sourcing, and device-drug compatibility expertise that has historically not been a unified discipline in pharma operations.
The pharmaceutical industry’s recognition of this workforce challenge is not new, but the urgency has increased.
A peer-reviewed perspective published in the European Journal of Pharmaceutical Sciences in 2026 by Maclean and colleagues documented the structural shift directly. Industry reports from the Association of British Pharmaceutical Industry, the World Economic Forum, and McKinsey have highlighted growing demand for data scientists, automation specialists, and digitally proficient process engineers in pharmaceutical settings. Traditional roles, including those in packaging and delivery, are expanding to incorporate digital tools and cross-disciplinary collaboration. The university-level pipeline, the authors note, has not kept pace.
ISPE’s March 2025 industry analysis confirmed the pattern. The pharmaceutical market is on track to reach $861.67 billion by 2028 at 6.3% CAGR, but 80% of pharmaceutical manufacturers report a mismatch between existing employee skills and evolving job requirements. 83% of biopharma supply chain leaders emphasize the need to upskill or reskill their workforce to support digital transformation, including in packaging and delivery functions.
The data describes the same problem from multiple angles: the talent profile pharmaceutical packaging and delivery now require did not exist as a developed category five years ago, and the talent pipeline has not yet adapted to produce it at scale.
The pharma manufacturers building credible packaging and delivery capability for 2026 and beyond share four characteristics.
They run formal hiring profile audits. Most pharma operations are still hiring against job descriptions written before 2023. The audit examines current packaging and delivery roles against the actual skill requirements of 2026-2030 product pipelines, identifies the gaps, and rewrites job descriptions to reflect what the work actually requires. The hiring profile audit is the prerequisite for everything else.
They build hybrid profiles intentionally. Few candidates exist with the full hybrid mechanical/software/human factors/sustainability/regulatory skill set required for modern packaging and delivery roles. The realistic strategy is to hire strong individual disciplines and build cross-disciplinary depth through structured rotation programs, deliberate cross-functional project assignments, and partnerships with universities that have been building integrated programs in industrial pharmacy and pharmaceutical engineering.
They source from medical devices and connected health, not just pharma. The talent pool with hybrid skill profiles is concentrated in medical device companies, connected health platforms, and consumer health products as much as in pharma manufacturing itself. Pharma manufacturers that limit their candidate pool to traditional pharma packaging recruiting are missing the talent that has actually built the modern skill profile.
They establish supplier and partnership ecosystems before scaling demand. Connected device components, sustainable materials, and platform autoinjector partnerships are concentrated among a small number of specialized suppliers. Pharma manufacturers that have built these supplier relationships before they need them are de-risking their delivery system roadmaps. Those treating supplier relationships as transactional procurement are finding capacity constraints when they try to scale.
The transformation of pharmaceutical packaging and delivery from downstream function to strategic differentiation category is not a temporary trend. It is the new structural baseline.
Three priorities belong on the next operations agenda for any pharma manufacturer with delivery system or packaging dependencies.
First, run a formal hiring profile audit for all packaging, delivery, and combination product roles. The output should compare current job descriptions against the skill requirements of the actual 2026-2030 product pipeline, identify gaps, and rewrite descriptions to reflect what the work now requires.
Second, evaluate whether internal development pathways exist to build hybrid mechanical/software/human factors/sustainability profiles from current talent. If they do not, building them through structured rotation programs, partnership with university industrial pharmacy programs, and cross-functional project assignments is multi-year infrastructure investment that needs to start now.
Third, examine the supplier and partnership ecosystem for connected devices, sustainable materials, and platform autoinjectors. Companies with established relationships will have access to capacity and innovation that companies without those relationships will not. The relationships need to be built before the scaling demand makes them harder to establish.
The packaging and delivery transformation is going to determine which pharma manufacturers maintain product differentiation through the next decade and which see their delivery systems become commodity components. The talent strategy that runs alongside the product strategy is the difference between those two outcomes.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company